Dr. Kim is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215Phone+1 617-632-6844Fax+1 617-632-4422
Education & Training
UMass Chan Medical SchoolFellowship, Hematology and Medical Oncology, 2014 - 2017- UMass Chan Medical SchoolResidency, Internal Medicine, 2010 - 2013
Geisel School of Medicine at DartmouthClass of 2010
Certifications & Licensure
RI State Medical License 2022 - 2026
VT State Medical License 2023 - 2026
MA State Medical License 2013 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Avo In R/R And Previously Untreated MCL Start of enrollment: 2021 Jul 02
- Copanlisib Plus Venetoclax in R/R DLBCL Start of enrollment: 2021 Sep 08
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- A Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in a Treatment-Naive CLL Population Enriched for High-Risk Disease.Matthew S Davids, Christine E Ryan, Benjamin L Lampson, Yue Ren, Svitlana Tyekucheva
Journal of Clinical Oncology. 2024-12-07 - A real-world comparison of commercial use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma.Andrew Looka, David A Qualls, Daniel Matthews, Robert A Redd, Christopher Sakellis
Blood Advances. 2024-11-15 - Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP.Ronald Nemec, Marielle Scherrer-Crosbie, Jeremy S Abramson, Robert Redd, Hannah K Gilman
Leukemia & Lymphoma. 2024-06-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
